Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project
Clementina López‐Medina(Hospital Universitario Reina Sofía), Pilar Font(Instituto Maimónides de Investigación Biomédica de Córdoba), J. Calvo-Gutiérrez(Instituto Maimónides de Investigación Biomédica de Córdoba), F. van Gaalen(Leiden University Medical Center), Anna Moltó(Inserm), Eduardo Collantes‐Estévez(Hospital Universitario Reina Sofía), Helena Marzo‐Ortega(University of Leeds), Salih Özgöçmen(Tokat Gaziosmanpaşa Üniversitesi), Yolanda Jiménez(Instituto Maimónides de Investigación Biomédica de Córdoba), Ruxandra Elena Schiotis(Iuliu Hațieganu University of Medicine and Pharmacy), Maxime Dougados(Délégation Paris 5), Carmen Castro(Instituto Maimónides de Investigación Biomédica de Córdoba)
Cited by 28
Related Papers
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
|Annals of the Rheumatic Diseases|2017|1.6k
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
|New England Journal of Medicine|2005|1.2k
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
|Annals of the Rheumatic Diseases|2011|988